SEC Form 4 · accession 0001209191-17-043852
Revance Therapeutics, Inc. · RVNC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lauren P Silvernail
Officer — CFO, CBO & Secretary
Period of report
Jun 30, 2017
Accepted (ET)
Jul 5, 2017 · 9:32 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001479290
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 30, 2017 | J | 604 | $18.3175 | A | 60,170 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These shares were acquired by Mrs. Silvernail under the Issuer's 2014 Employee Stock Purchase Plan on June 30, 2017 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).